Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3985297 · 1 trial · 1 indication
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
| Arm | Type | Description |
|---|---|---|
| Part A: LY3985297 (Cohorts 1-8) | EXPERIMENTAL | Single ascending dose of LY3985297 administered either intravenously (IV) or subcutaneously (SC). Cohort 5,6 and 7 is conducted in Japanese or Chinese participants. |
| Part B: LY3985297 (Cohorts 1-4) | EXPERIMENTAL | Multiple ascending dose of LY3985297 administered either IV or SC. |
| Placebo Comparator: Part A and B: Placebo | PLACEBO_COMPARATOR | Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3985297 | DRUG | Administered either IV or SC. |
| Placebo | DRUG | Administered either IV or SC. |
Inclusion Criteria: * Participants must be overtly healthy, as determined by medical evaluation. * Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, and a minimum body weight of 45.0 kg. * Participants must be assigned male or female at birth and not of childbear...
LY3985297 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a first-in-human Phase 1 trial in healthy adult participants. The specific disease or condition it is intended to treat has not been disclosed, so its therapeutic use is not publicly defined at this stage.
LY3985297 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating this investigational small molecule.
LY3985297 is in Phase 1 clinical development. Its only recorded trial, a first-in-human study in healthy participants, has been completed. The drug is investigational and is not approved by the FDA for any indication.
LY3985297 has been evaluated in one clinical trial, NCT06395012, titled A First-In-Human Study of LY3985297 in Healthy Participants. The Phase 1 trial enrolled 140 participants in the United States, was randomized, double-blind, and placebo-controlled, and is now completed.
The molecular target of LY3985297 has not been disclosed. It is described as a small molecule, but no target or target class information is publicly available, so its mechanism of action cannot be stated.
No. LY3985297 is an investigational drug in Phase 1 development and has not been approved by the FDA. Its only completed trial was a first-in-human study in healthy volunteers, which is an early stage of clinical testing.